Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Hematologic Neoplasms 2COVID-19 2Skin Neoplasms 1Respiratory Sounds 1Respiratory Distress Syndrome 1Pneumonia, Viral 1Pharmacokinetics 1Neoplasms 1Lymphoma, Follicular 1Cytokine Release Syndrome 1Crohn Disease 1Bronchiolitis Obliterans Syndrome 1Asthma 1Adenomatous Polyposis Coli 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Azithromycin × Clear all
NCT04341207 2020-04-10

ONCOVID

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Unknown
1,000 enrolled

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡